Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06568237 · ClinicalTrials.gov registry record · Phase 2

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

A Phase 2 study of Multiple System Atrophy, sponsored by Teva Branded Pharmaceutical Products R&D.

Recruiting
Registry status
Phase 2
Development phase
350
Enrollment target
20
Study locations

NCT06568237 is a Phase 2 study of Multiple System Atrophy that is actively recruiting participants, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 350 participants, above the 257-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (36% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06568237, a Phase 2 study of Multiple System Atrophy, is actively recruiting participants, sponsored by Teva Branded Pharmaceutical Products R&D.

RECRUITING
Registry status
Phase 2
Development phase
350 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.

Conditions Studied

Multiple System Atrophy

Interventions

  • DRUG Placebo
  • DRUG TEV-56286

Study Locations (20)

California

  • Teva Investigational Site 15554 - La Jolla
  • Teva Investigational Site 15545 - Los Angeles

Florida

  • Teva Investigational Site 15544 - Boca Raton
  • Teva Investigational Site 15555 - Tampa

New York

  • Teva Investigational Site 15549 - New York
  • Teva Investigational Site 15551 - New York

Pennsylvania

  • Teva Investigational Site 15735 - Hershey
  • Teva Investigational Site 15548 - Pittsburgh

Other

  • Teva Investigational Site 35290 - Bordeaux
  • Teva Investigational Site 35289 - Marseille

District of Columbia

  • Teva Investigational Site 15547 - Washington D.C.

Illinois

  • Teva Investigational Site 15550 - Chicago

Kansas

  • Teva Investigational Site 15546 - Kansas City

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2024-10-02
Est. Completion 2027-09-15
Phase Phase 2

Sponsor

Teva Branded Pharmaceutical Products R&D

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06568237

The ClinicalTrials.gov registry entry for NCT06568237 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 257-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (36% higher). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple System Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06568237 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT06568237 about?

NCT06568237 is a clinical study titled "A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy". The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to...

What is the current status of trial NCT06568237?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2024-10-02. Estimated completion is 2027-09-15.

What conditions does trial NCT06568237 study?

This clinical trial studies the following conditions: Multiple System Atrophy.

What interventions are being tested in trial NCT06568237?

The interventions under investigation include: Placebo (DRUG), TEV-56286 (DRUG).

Who is sponsoring clinical trial NCT06568237?

This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06568237 being conducted?

This trial has 20 study locations across California, District of Columbia, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple System Atrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple System Atrophy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.